CELG News and Press, Celgene Corporation From 05/16/19

(Source: imgflip ) Long-time readers will know that I'm a passionate value investor, always looking to buy quality companies for my retirement portfolio (100% of my life savings) at discounts to fair value. Because as Buffett famously said, " it's far better to buy a wonderful company a...

The European Commission has approved two of Celgene’s IMiD ® -based combination regimens: REVLIMID in combination with bortezomib and dexamethasone (RVd) in adult patients with previously untreated multiple myeloma who are not eligible for transplant IMNOVID in ...

Celgene ( CELG ) has seen its stock price improve dramatically since it was announced it would be acquired by Bristol-Myers Squibb ( BMY ). The deal was approved by stockholders of both companies and looks likely to go through this year, unless there are regulatory objections. Currently, Celge...

Presentations include innovative cancer research, including novel CAR T technology, as well as key disease areas, including myelofibrosis and multiple myeloma Celgene Corporation (NASDAQ: CELG) today announced that data from more than 40 company-sponsored, global alliance and investig...

The FDA designates Celgene's (NASDAQ: CELG ) POMALYST (pomalidomide) a Breakthrough Therapy for the treatment of patients with human immunodeficiency virus (HIV)-positive Kaposi's sarcoma (KS) who have previously received systemic chemotherapy, as well as patients with HIV‐ne...

Celgene plans to submit sNDA by end of 2019 Celgene plans additional studies with the AIDS Malignancy Consortium in U.S. and sub-Saharan Africa Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy desi...

This article is part of a series that provides an ongoing analysis of the changes made to David Abrams’ 13F portfolio on a quarterly basis. It is based on Abrams’ regulatory 13F Form filed on 05/10/2019. Please visit our Tracking David Abrams’ Abrams Capital Management ...

With Google Ventures ( GOOG ) (GOOLG) and Celgene ( CELG ) behind Ideaya Biosciences ( IDYA ), the company will be followed closely by the market. The most favorable is that the company’s portfolio includes more than six biomarkers, which should permit the company to target a signific...

This article is part of a series that provides an ongoing analysis of the changes made to Kahn Brothers' 13F stock portfolio on a quarterly basis. It is based on Kahn Brothers' regulatory 13F Form filed on 05/06/2019. Please visit our Tracking Kahn Brothers Portfolio series to get an idea ...

NEW YORK , May 10, 2019 /PRNewswire/ -- Lyfebulb, a chronic disease-focused, patient-empowerment platform that connects patients with industry to support user-driven innovation, and Celgene Corporation (NASDAQ: CELG) announced the 10 finalists chosen for the Lyfebulb-Celgene 2019 "Address...